Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.40 |
| ▸ | BRAF | P15056 | 5/20 | 0.39 |
| ▸ | RAF1 | P04049 | 3/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP7 | P09237 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.35 |
| ▸ | CSF1R | P07333 | 4/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7123889 | 0.88 | EZH2 (0.39) | MMP2MMP7MMP9MMP13EZH2 | |
| SCHEMBL7123911 | 0.87 | MAPK14 (0.43) | KDRBRAFRAF1MAPK14CSF1R | |
| SCHEMBL7116456 | 0.86 | EGLN1 (0.39) | MMP2MMP7MMP9MMP13EZH2 | |
| SCHEMBL7125176 | 0.86 | HRH3 (0.42) | MMP2MMP7MMP9MMP13EZH2 | |
| SCHEMBL7117240 | 0.86 | TAS1R3 (0.43) | KDRMMP2MMP7MMP9MMP13 | |
| SCHEMBL7116944 | 0.85 | HPGD (0.46) | MMP2MMP7MMP9MMP13EZH2 | |
| SCHEMBL7116799 | 0.84 | KDR (0.39) | KDREPHX2MMP2MMP7MMP9 | |
| SCHEMBL7125270 | 0.84 | LOXL2 (0.38) | MMP2MMP7MMP9MMP13 | |
| SCHEMBL7116320 | 0.83 | SCN9A (0.39) | KDRBRAFRAF1MMP2MMP7 | |
| SCHEMBL7117129 | 0.83 | CHRNA7 (0.37) | EZH2RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-10 | — | — | US | claimed |
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | CYP7B1, UGT2B7, CYP1B1 | KDR 2299/4885BRAF 3842/4885RAF1 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.